Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4)

Halyard, Michele Y.; Jatoi, Aminah; Sloan, Jeff A.; Bearden, James D.; Vora, Sujay A.; Atherton, Philip J.; Perez, Edith A.; Soori, Gammi; Zalduendo, Anthony C.; Zhu, Angela; Stella, Philip J.; Loprinzi, Charles L.

doi:10.1016/j.ijrobp.2006.10.046

Cited by 98 publications

(79 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown a prevalence of metallic taste in cancer patients treated with chemotherapy ranging from 10% to 78% (16)(17)(18)(19)(20)(21)(22). Also, metallic taste in patients treated with radiotherapy has been reported previously (23). To our knowledge, this is the first study that reports metallic taste in patients receiving targeted therapy.…”

Section: Discussionsupporting

confidence: 59%

Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

IJpma

Timmermans

Renken

et al. 2016

Nutrition and Cancer

View full text Add to dashboard Cite

A metallic taste is reported by cancer patients as a side effect of systemic therapy. Despite the high prevalence, this taste alteration has received limited attention. The present study investigated: 1) the prevalence of metallic taste in cancer patients treated with systemic therapy; 2) possible predictors of metallic taste; and 3) characteristics of metallic taste. A heterogeneous population of 127 cancer patients, who had received systemic treatment in the past year or were still on treatment, completed a questionnaire developed for this study. Fifty-eight of 127 (46%) patients reported taste changes in the preceding week. Of these patients, 20 (34%) reported a metallic taste. Patients treated with chemotherapy, concomitant radiotherapy, as well as targeted therapy reported metallic taste. Women experienced metallic taste more often than men. Patients experiencing a metallic taste also reported more frequently that they were bothered by sour food and that everything tasted bitter. The experience of metallic taste was highly variable among patients. In conclusion, metallic taste is a frequently experienced taste alteration by cancer patients. Patients treated with chemotherapy, concomitant radiotherapy, and targeted therapy are all at risk for this taste alteration. However, not all patients reported this alteration as bothersome.

show abstract

Section: Discussionsupporting

confidence: 59%

Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

IJpma

Timmermans

Renken

et al. 2016

Nutrition and Cancer

View full text Add to dashboard Cite

show abstract

“…This is followed by general abnormal taste and a reduction in taste acuity. 199,201,207,[209][210][211][212][213] Umami declines during the third week of RT. After RT, taste sensitivity usually recovers within several months after the resolution of mucosal damage.…”

Section: Taste Alterations In Cancermentioning

confidence: 99%

“…After RT, taste sensitivity usually recovers within several months after the resolution of mucosal damage. 184,209,211,[213][214][215][216][217][218] However, reduced taste sensitivity may continue indefinitely. Persisting taste loss may be due to damage to taste receptors 214,219 and hyposalivation.…”

Section: Taste Alterations In Cancermentioning

confidence: 99%

“…235 Another trial comparing zinc sulfate (45 mg/day) with placebo in 169 patients during RT found fewer patients in the zinc group reported taste changes compared with the placebo group (73% vs 84%), but these results were not significant. 213 Zinc supplements may be considered in patients with persistent taste complaints. 209 Clonazepam may affect taste sensation.…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

431

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

“…Out of the 12 reviewed papers half of them were randomized control trials, [3,20,[26][27][28][29] with four of them double blinded, placebo control. [3,20,26,27] Two studies were cross sectional studies, [30,31] and there were three prospective longitudinal studies, [32][33][34] one was a case study, [34] and another one quasi experimental study. [35] Sample size ranged from two to 531, with commonest diagnosis of head and neck cancer followed by breast cancer, lung cancer, gastrointestinal (GI) cancer, and a wide range of other cancer diagnosis.…”

Section: Resultsmentioning

confidence: 99%

Management of Dysgeusia related to Cancer

Munankarmi

2017

J Lumbini Med Coll

View full text Add to dashboard Cite

a ----------------------------------------------- ABSTRACT:Introduction: Taste change due to cancer is a notorious side effect, adversely affecting appetite and weight. Even though taste change or dysgeusia is one of the major causes of poor nutritional status in cancer survivors, it is not addressed as a significant problem and is often left untreated. The main purpose of this review is to explore current knowledge of pharmacological and behavioral interventions for the treatment of cancer related taste change. Methods: This systematic review was conducted in accordance with PRISMA guidelines to identify original articles on taste change. Multiple databases including; Scopus, Medline, EMBASE, CINAHL, and all databases via Pro quest were searched for original articles or studies related to taste change caused by cancer or its treatment. Relevant articles were subjected to a full text evaluation and assessed by Critical appraisal skills program (CASP) guidelines and the Effective public health practice project (EPHPP) instrument. Results: The search revealed 12 eligible studies, six of which were randomized controlled trials. Most of the studies used a standardized validated tool to measure taste change. Dysgeusia is common in cancer, 14 to 100% cancer patient report it. Pharmacological management with zinc remains inconclusive as one study reports it as beneficial and two other studies reported null effect. Few studies suggested dietary modifications such as use of sugary, salty foods that are helpful to reduce the effect of dysgeusia. Conclusion: Dietary counseling and informing the patient well about self-care strategies before treatment has consistently shown positive results on taste change, with strong statistical power. Other potential treatments for dysgeusia such as zinc, amifostine, and megestrol acetate gave inconsistent results.

show abstract

Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4)

Cited by 98 publications

References 5 publications

Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study

Oral complications of cancer and cancer therapy

Management of Dysgeusia related to Cancer

Contact Info

Product

Resources

About